These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 26938702

  • 1. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb 29; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract] [Full Text] [Related]

  • 2. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S, Gourley C, Kumar R, Geuna E, Ern Ang J, Rye T, Chen LM, Shapira-Frommer R, Friedlander M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA.
    Oncotarget; 2017 Jul 18; 8(29):47154-47160. PubMed ID: 28454085
    [Abstract] [Full Text] [Related]

  • 3. Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.
    Support Care Cancer; 2020 May 18; 28(5):2435-2442. PubMed ID: 32048043
    [Abstract] [Full Text] [Related]

  • 4. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A.
    Lancet Oncol; 2011 Sep 18; 12(9):852-61. PubMed ID: 21862407
    [Abstract] [Full Text] [Related]

  • 5. The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer.
    Nirsimloo R, Gourley C.
    Expert Rev Anticancer Ther; 2016 Jun 18; 16(6):597-603. PubMed ID: 27115428
    [Abstract] [Full Text] [Related]

  • 6. Safety evaluation of olaparib for treating ovarian cancer.
    Lheureux S, Bowering V, Karakasis K, Oza AM.
    Expert Opin Drug Saf; 2015 Aug 18; 14(8):1305-16. PubMed ID: 26051946
    [Abstract] [Full Text] [Related]

  • 7. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
    Poveda AM, Davidson R, Blakeley C, Milner A.
    Future Oncol; 2019 Nov 18; 15(32):3651-3663. PubMed ID: 31553234
    [Abstract] [Full Text] [Related]

  • 8. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U.
    Lancet Oncol; 2016 Nov 18; 17(11):1579-1589. PubMed ID: 27617661
    [Abstract] [Full Text] [Related]

  • 9. Olaparib, a new hope for ovarian cancer.
    Samoon Z, Jabbar AA.
    Indian J Cancer; 2020 Nov 18; 57(3):346-347. PubMed ID: 32675438
    [No Abstract] [Full Text] [Related]

  • 10. Olaparib for the treatment of ovarian cancer.
    Bornstein E, Jimeno A.
    Drugs Today (Barc); 2016 Jan 18; 52(1):17-28. PubMed ID: 26937492
    [Abstract] [Full Text] [Related]

  • 11. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
    Munroe M, Kolesar J.
    Am J Health Syst Pharm; 2016 Jul 15; 73(14):1037-41. PubMed ID: 27385701
    [Abstract] [Full Text] [Related]

  • 12. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N, Copur MS.
    Oncology (Williston Park); 2019 Jul 15; 33(7):. PubMed ID: 31365755
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    J Clin Oncol; 2015 Jan 20; 33(3):244-50. PubMed ID: 25366685
    [Abstract] [Full Text] [Related]

  • 15. Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
    Miller RE, Crusz SM, Ledermann JA.
    Future Oncol; 2019 Jun 20; 15(16):1845-1853. PubMed ID: 31037967
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN, Monk BJ.
    Oncologist; 2016 Aug 20; 21(8):954-63. PubMed ID: 27256873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.